PhytoMedical said that in addition to his appointment as president and CEO, Mr Lynch will also serve on the company’s board of directors.
Mr Lynch brings over two decades of industry experience across strategic, operational and entrepreneurial roles within pharma, private and public specialty pharmaceutical companies, and international consulting.
Recently, Dr Lynch has provided independent advisory services to several biopharmaceutical companies, including Drais Pharmaceuticals, a venture-backed, oncology company developing anti-tumor drugs, as its acting chief business officer.
Greg Wujek, president, CEO and director of PhytoMedical Technologies, said: “I’m proud to have Dr Lynch take leadership of our company, and especially look forward to capitalizing on his industry experience, which spans more than 20 years and ranges from the development and launch of new compounds to successfully consummating deals with big pharma.
“Especially helpful to advancing our pipeline and creating an international presence for our company is Dr. Lynch’s unique blend of worldwide pharmaceutical product and business development expertise, and scientific know-how.”